Skyrizi carries a list price of roughly $30,000 to $35,000 per dose, depending on the formulation, putting the annual cost at around $120,000 for many patients. That sticker shock is real, and it stems from a combination of factors: the complexity of manufacturing biologic drugs, patent protections that block competition, AbbVie’s pricing strategy, and a rebate system that actually rewards higher list prices.
Biologic Drugs Cost Far More to Make
Skyrizi (risankizumab) is a monoclonal antibody, a type of drug grown inside living mammalian cells rather than assembled from chemical ingredients the way a traditional pill is. Those cells produce the desired antibody, but they also generate a mess of other proteins, DNA fragments, and cellular debris that all has to be separated out before the drug is safe to inject.
One key step in that purification process, called affinity chromatography, involves pumping the raw solution through massive columns packed with specialized particles that grab onto the antibodies and let everything else wash away. A single one of these columns can cost more than $10 million. Multiply that across the many purification and quality-control steps required, and the manufacturing bill for a biologic dwarfs what it costs to press a small-molecule pill. The finished product also needs cold-chain shipping and careful storage, adding another layer of expense that conventional drugs don’t carry.
Patent Protection Blocks Cheaper Alternatives
AbbVie’s composition-of-matter patent on risankizumab isn’t expected to expire until 2033. On top of that, biologics receive 12 years of regulatory exclusivity under federal law, meaning no biosimilar (the biologic equivalent of a generic) can win FDA approval during that window. A potential six-month extension is available if the manufacturer conducts pediatric studies. Until those protections lapse, AbbVie faces zero direct competition from lower-cost copies of Skyrizi, giving it full control over pricing.
AbbVie’s Bundled Rebate Strategy
The list price you see isn’t necessarily what insurers pay. Pharmacy benefit managers (PBMs), the middlemen who negotiate drug costs on behalf of health plans, receive confidential rebates from manufacturers. These end-of-year payments, based on total prescriptions filled, can represent a significant percentage of a drug’s list price. The exact rebate figures for Skyrizi are kept secret, but the broader system creates a perverse incentive: higher list prices generate larger rebates, which PBMs and health plans have come to depend on. As one industry observer put it, “the large intermediaries are wedded to inflated sticker prices.”
AbbVie has used Skyrizi’s lack of biosimilar competition as leverage in these negotiations. According to PBM officials, the company has warned health plans that if they favor biosimilar alternatives to Humira (AbbVie’s older blockbuster), they’ll lose rebates not just on Humira but on purchases of Skyrizi and its other newer drug, Rinvoq, both listed at about $120,000 a year. That kind of bundling keeps Skyrizi’s position on insurance formularies secure while maintaining its high price tag.
What Different Formulations Actually Cost
Skyrizi comes in several delivery formats, and their retail prices vary:
- Prefilled injection pen (150 mg): about $31,000 per dose
- Prefilled syringe (150 mg): about $33,800 per dose
- On-body injector kit (180 mg): about $33,200 per dose
- On-body injector kit (360 mg): about $35,400 per dose
With a GoodRx coupon, all four formats drop to roughly $23,500 to $23,800 per dose. That’s still an enormous sum, but it illustrates the gap between the posted retail price and what some buyers actually pay.
R&D Costs Baked Into the Price
Bringing any biologic to market requires years of preclinical work followed by multiple rounds of human trials. Skyrizi has been tested across several conditions, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Each new indication means additional large-scale clinical trials enrolling thousands of patients, with costs that can run into hundreds of millions of dollars per trial. AbbVie recoups that investment through the drug’s price during the years it has patent exclusivity.
This isn’t unique to Skyrizi. The entire biologic drug class follows the same model: massive upfront research spending, expensive manufacturing, and a limited window of market exclusivity that encourages manufacturers to price aggressively while they can.
How Patients Reduce Their Out-of-Pocket Cost
If you have commercial insurance, AbbVie’s Skyrizi Complete savings program can cover a portion of your copay, up to a maximum of $14,000 per calendar year. For many commercially insured patients, that brings the personal cost down to as little as $5 per dose, though the benefit depends on your specific plan.
Patients on Medicare or Medicaid don’t qualify for the copay card. Some may be eligible for AbbVie’s separate patient assistance program, which provides the drug at no cost to people who meet income requirements. Specialty pharmacies and hospital financial counselors can also help identify state or nonprofit programs that offset costs. The gap between Skyrizi’s list price and what an individual actually pays varies wildly depending on insurance type, plan design, and which assistance programs apply.
Why the Price Is Unlikely to Drop Soon
With patent protection extending to 2033 and no biosimilar pathway open before then, the market dynamics that support Skyrizi’s current price aren’t changing in the near term. AbbVie has little financial incentive to lower the list price when the rebate system rewards keeping it high, and PBMs have little incentive to push back when their own revenue is tied to those same inflated numbers. Until biosimilar competition arrives or the rebate structure changes through legislation, Skyrizi’s cost will largely stay where it is.